David Heal, PhD, DSc, FRSC, FBPhS, Executive Director, DevelRx Ltd.
Jack Henningfield, PhD, Vice President, Research, Health Policy, and Abuse Liability, Pinney Associates
Charles France, PhD, Robert A. Welch Distinguished University Chair in Chemistry, Professor of Pharmacology, and Professor of Psychiatry, UT Health San Antonio, Long School of Medicine, Department of Pharmacology
Judy Ashworth, MD, Vice President, Rx Strategic Services and Chief Medical Officer, Pinney Associates
Building on the Foundation of the FDA 2017 Guidance on the Assessment of Abuse Potential, we explored refinements and innovations in non-clinical and clinical testing procedures necessary to identify and quantify the degree of abuse and dependence risks posed by these drugs.
Presented at the College on Problems of Drug Dependence 83rd Annual Scientific Virtual Meeting, June 21–24, 2021